▁Introduction 10.375
: 6.5078125
<0x0A> 4.01953125
M 4.5390625
el 3.818359375
an 3.662109375
oma 0.78466796875
▁is 0.88525390625
▁an 2.998046875
▁ag 0.5048828125
gress 0.0005822181701660156
ive 0.004428863525390625
▁form 1.13671875
▁of 0.004146575927734375
▁skin 0.330810546875
▁cancer 0.00640869140625
▁that 1.013671875
▁can 1.9140625
▁met 4.11328125
ast 9.238719940185547e-05
as 0.01557159423828125
ize 0.035308837890625
▁rapidly 4.12890625
▁if 4.0546875
▁left 1.021484375
▁un 0.083740234375
tre 0.0180511474609375
ated 0.0001188516616821289
. 0.1737060546875
▁Over 6.15234375
▁the 1.2578125
▁years 2.2734375
, 0.236083984375
▁adv 5.0234375
anc 1.205078125
ements 0.00015652179718017578
▁in 0.2325439453125
▁medical 3.705078125
▁science 1.814453125
▁have 0.1976318359375
▁led 2.03515625
▁to 0.026611328125
▁the 1.3466796875
▁development 0.37646484375
▁of 0.0219268798828125
▁ground 8.953125
bre 0.2568359375
aking 7.68899917602539e-05
▁treat 1.46875
ments 0.0001933574676513672
, 2.419921875
▁not 5.9453125
ably 0.63037109375
▁imm 1.51953125
une 3.37890625
▁check 1.123046875
point 0.01036834716796875
▁in 0.25732421875
hib 0.00012731552124023438
itors 0.15673828125
▁and 2.41796875
▁adj 6.56640625
uv 0.026092529296875
ant 0.004230499267578125
▁ther 0.52197265625
ap 0.403076171875
ies 9.584426879882812e-05
. 0.6162109375
▁These 3.009765625
▁novel 4.19140625
▁approaches 2.39453125
▁have 0.7841796875
▁shown 3.40625
▁great 2.64453125
▁potential 3.103515625
▁in 0.67138671875
▁ach 5.41015625
ieving 6.73532485961914e-05
▁long 1.8623046875
- 0.035552978515625
term 0.0933837890625
▁rem 1.7548828125
ission 0.8984375
▁and 1.2587890625
▁impro 2.9765625
ving 0.0018701553344726562
▁surv 2.0625
ival 0.0039825439453125
▁rates 0.63037109375
▁for 1.9375
▁patients 0.62744140625
▁at 5.74609375
▁different 7.4765625
▁stages 0.2027587890625
▁of 0.07373046875
▁mel 1.70703125
an 0.00011301040649414062
oma 0.0033473968505859375
. 0.3251953125
▁This 3.09765625
▁ess 7.8046875
ay 0.001148223876953125
▁a 1.685546875
ims 0.0004100799560546875
▁to 0.02618408203125
▁discuss 2.369140625
▁the 0.380126953125
▁adv 4.4140625
anc 0.474609375
ements 0.0001093149185180664
▁in 0.368408203125
▁these 5.17578125
▁treat 1.86328125
ments 0.00012254714965820312
, 1.4541015625
▁their 1.5009765625
▁imp 4.3515625
lications 0.052093505859375
▁for 1.5947265625
▁patients 1.34375
, 0.344482421875
▁and 0.103515625
▁illustrate 10.859375
▁their 1.4619140625
▁impact 2.576171875
▁on 0.237060546875
▁surv 5.14453125
ival 0.0205535888671875
▁rates 0.61572265625
▁through 6.44140625
▁the 1.5615234375
▁case 3.216796875
▁of 0.740234375
▁Mr 6.359375
. 0.297119140625
▁B 3.91796875
. 0.46826171875
<0x0A> 0.52783203125
Ad 2.90234375
van 1.990234375
c 0.2152099609375
ements 0.0008401870727539062
▁in 0.0804443359375
▁Mel 1.7861328125
an 0.0006260871887207031
oma 0.0025615692138671875
▁Tre 0.296630859375
at 0.000659942626953125
ment 0.363037109375
: 2.78515625
<0x0A> 0.487548828125
Im 2.294921875
m 0.31787109375
une 0.0180511474609375
▁check 0.81396484375
point 0.0170745849609375
▁in 0.035614013671875
hib 0.00027942657470703125
itors 0.044891357421875
▁such 5.1015625
▁as 0.0040435791015625
▁p 1.6767578125
emb 0.0016002655029296875
rol 0.00299835205078125
iz 0.0022735595703125
um 0.0027637481689453125
ab 0.0002651214599609375
▁and 1.0166015625
▁n 0.0653076171875
iv 0.0014743804931640625
ol 0.0003895759582519531
um 0.0009541511535644531
ab 0.0007681846618652344
▁have 0.63720703125
▁revolution 1.443359375
ized 0.027374267578125
▁mel 1.857421875
an 9.763240814208984e-05
oma 0.00225067138671875
▁treatment 0.1884765625
. 0.953125
▁These 0.919921875
▁dru 1.6064453125
gs 4.0531158447265625e-06
▁work 2.607421875
▁by 0.09832763671875
▁blocking 1.0478515625
▁the 0.86669921875
▁interaction 1.9267578125
▁between 0.480712890625
▁cancer 3.291015625
▁cells 0.1748046875
▁and 0.03314208984375
▁imm 1.859375
une 0.00991058349609375
▁in 7.7890625
hib 0.031829833984375
itory 0.3359375
▁mole 1.3154296875
cules 0.00308990478515625
, 1.4453125
▁thus 3.544921875
▁activ 4.3359375
ating 0.000743865966796875
▁the 0.2900390625
▁imm 0.405029296875
une 0.0016546249389648438
▁system 0.09326171875
▁to 0.65673828125
▁recognize 2.498046875
▁and 0.2327880859375
▁eliminate 1.8603515625
▁cancer 1.09375
▁cells 0.087646484375
. 0.1363525390625
▁They 3.369140625
▁have 0.498291015625
▁demonstrated 2.759765625
▁remarkable 3.0703125
▁success 3.064453125
▁in 0.117919921875
▁ach 4.79296875
ieving 2.2649765014648438e-05
▁dur 2.669921875
able 0.0011873245239257812
▁responses 1.32421875
▁and 1.994140625
▁prolong 1.1552734375
ed 0.267333984375
▁surv 0.41015625
ival 0.00736236572265625
▁rates 1.2705078125
▁in 0.488037109375
▁met 4.8515625
ast 0.00040340423583984375
atic 0.01410675048828125
▁mel 0.0771484375
an 7.092952728271484e-05
oma 0.01165771484375
▁patients 0.310546875
. 0.486328125
<0x0A> 1.3505859375
Add 5.03125
itionally 0.0712890625
, 0.0018720626831054688
▁adj 2.7109375
uv 0.0022640228271484375
ant 0.0008854866027832031
▁ther 0.128173828125
ap 0.1961669921875
ies 4.017353057861328e-05
, 2.099609375
▁such 0.310791015625
▁as 0.0021724700927734375
▁inter 2.57421875
fer 0.0274810791015625
on 0.05877685546875
▁ther 3.2421875
apy 0.05413818359375
, 0.6552734375
▁target 4.27734375
ed 1.4287109375
▁ther 0.5478515625
apy 0.5234375
, 0.2071533203125
▁and 0.266357421875
▁cancer 6.60546875
▁v 0.268798828125
acc 0.00016570091247558594
ines 0.217041015625
, 0.1939697265625
▁have 0.347900390625
▁played 3.6171875
▁a 0.57275390625
▁p 2.5703125
iv 9.417533874511719e-06
otal 1.4901161193847656e-05
▁role 0.00270843505859375
▁in 0.00421142578125
▁reducing 3.84765625
▁disease 4.3125
▁rec 0.994140625
urrence 0.0167236328125
▁and 0.314697265625
▁impro 0.82177734375
ving 2.8371810913085938e-05
▁overall 1.689453125
▁surv 0.08807373046875
ival 0.003261566162109375
▁rates 0.5810546875
▁post 7.23046875
- 0.495849609375
s 2.8046875
urg 0.0003008842468261719
ery 0.09765625
. 0.38671875
▁These 1.18359375
▁ther 1.0498046875
ap 0.00150299072265625
ies 9.179115295410156e-06
▁are 2.13671875
▁often 2.287109375
▁tail 5.234375
ored 0.005031585693359375
▁to 0.127197265625
▁the 0.5205078125
▁specific 1.1533203125
▁mole 3.5078125
cular 0.0017614364624023438
▁characteristics 0.9951171875
▁of 0.044921875
▁mel 2.6484375
an 5.352497100830078e-05
oma 0.043060302734375
, 1.2470703125
▁ens 3.6953125
uring 5.447864532470703e-05
▁a 2.96875
▁patient 4.6875
- 2.59765625
center 2.962890625
ed 0.00039958953857421875
▁approach 0.356201171875
. 1.4580078125
<0x0A> 0.7109375
Imp 2.490234375
lications 0.412841796875
▁for 0.3876953125
▁Pat 0.410888671875
ients 0.0219268798828125
▁at 5.3359375
▁D 0.041168212890625
ifferent 0.0007219314575195312
▁St 0.048553466796875
ages 7.283687591552734e-05
: 2.427734375
<0x0A> 0.006412506103515625
For 3.6796875
▁patients 0.23974609375
▁with 1.515625
▁early 0.880859375
- 0.56103515625
stage 0.0170135498046875
▁mel 0.045806884765625
an 8.881092071533203e-05
oma 0.00870513916015625
, 0.11004638671875
▁imm 1.5087890625
une 0.225341796875
▁check 0.0221405029296875
point 0.0027713775634765625
▁in 0.00885772705078125
hib 5.245208740234375e-05
itors 0.039031982421875
▁have 1.396484375
▁shown 1.5419921875
▁prom 1.93359375
ising 7.522106170654297e-05
▁out 2.66796875
comes 0.0005216598510742188
▁for 4.953125
▁reducing 3.890625
▁the 1.5009765625
▁risk 0.4345703125
▁of 0.01119232177734375
▁rec 1.02734375
urrence 0.012237548828125
. 1.640625
▁Studies 4.31640625
▁have 0.08563232421875
▁shown 0.32470703125
▁that 0.07586669921875
▁patients 1.162109375
▁with 1.0556640625
▁Stage 3.16015625
▁III 4.78125
▁mel 0.60205078125
an 2.5987625122070312e-05
oma 0.0098419189453125
▁who 0.58837890625
▁receive 2.326171875
▁adj 1.8671875
uv 0.0010433197021484375
ant 7.343292236328125e-05
▁ther 0.65478515625
apy 0.15576171875
▁with 1.021484375
▁imm 2.3203125
une 0.044403076171875
▁check 0.035430908203125
point 0.004024505615234375
▁in 0.005519866943359375
hib 5.1021575927734375e-05
itors 0.052398681640625
▁experienced 5.89453125
▁significantly 3.87109375
▁better 3.03515625
▁rec 5.44921875
urrence 0.0013790130615234375
- 0.1290283203125
free 0.00997161865234375
▁surv 0.244384765625
ival 0.002986907958984375
▁compared 2.29296875
▁to 0.1453857421875
▁traditional 8.953125
▁treat 2.150390625
ments 0.00010037422180175781
. 0.7021484375
▁This 2.3125
▁implies 5.3515625
▁that 0.0230560302734375
▁these 2.28515625
▁ther 1.2490234375
ap 0.0022430419921875
ies 9.298324584960938e-06
▁can 1.453125
▁potentially 3.259765625
▁convert 10.0625
▁a 2.1640625
▁dead 6.54296875
ly 0.0022258758544921875
▁disease 0.5087890625
▁into 0.2034912109375
▁a 0.1873779296875
▁manage 0.26611328125
able 0.0003650188446044922
▁condition 1.5947265625
▁in 3.560546875
▁the 2.06640625
▁long 2.759765625
▁term 1.5224609375
. 0.080322265625
<0x0A> 0.2220458984375
In 2.568359375
▁patients 3.302734375
▁with 0.1607666015625
▁advanced 1.4150390625
- 0.71875
stage 0.006378173828125
▁mel 0.0297698974609375
an 0.00012505054473876953
oma 0.0015468597412109375
, 0.0433349609375
▁imm 1.052734375
une 0.055816650390625
▁check 0.00875091552734375
point 0.0021572113037109375
▁in 0.004093170166015625
hib 1.5854835510253906e-05
itors 0.020050048828125
▁have 0.31982421875
▁provided 4.00390625
▁previously 9.3203125
▁un 0.181396484375
seen 2.57421875
▁levels 2.845703125
▁of 0.0007028579711914062
▁control 3.916015625
▁over 1.0556640625
▁the 0.923828125
▁disease 0.193603515625
. 0.48095703125
▁The 3.1171875
▁use 3.080078125
▁of 0.0009675025939941406
▁p 3.908203125
emb 0.0055999755859375
rol 0.00025391578674316406
iz 0.0009140968322753906
um 0.0009455680847167969
ab 0.0001271963119506836
▁has 2.279296875
▁yield 5.57421875
ed 0.0002371072769165039
▁remarkable 2.51953125
▁results 0.82080078125
, 1.890625
▁with 0.43896484375
▁studies 4.16015625
▁finding 3.009765625
▁that 0.406494140625
▁patients 0.9423828125
▁achieved 5.31640625
▁higher 7.41796875
▁objective 6.15234375
▁response 0.275634765625
▁rates 0.064453125
▁and 0.91552734375
▁longer 0.900390625
▁pro 1.771484375
gression 0.00032329559326171875
- 0.0099639892578125
free 0.0016241073608398438
▁surv 0.026275634765625
ival 0.04022216796875
▁compared 1.1865234375
▁to 0.03656005859375
▁conventional 3.021484375
▁chem 3.328125
other 0.021453857421875
apy 0.12286376953125
. 0.297607421875
▁This 1.6787109375
▁offers 6.14453125
▁renew 6.86328125
ed 0.00013709068298339844
▁hope 0.0131378173828125
▁and 4.3046875
▁prolong 7.87890625
ed 0.015411376953125
▁surv 0.439697265625
ival 0.004970550537109375
▁for 0.89453125
▁individuals 5.6796875
▁facing 3.75390625
▁advanced 1.943359375
▁mel 1.1044921875
an 5.5670738220214844e-05
oma 0.006374359130859375
. 0.1619873046875
<0x0A> 0.04693603515625
The 3.16015625
▁Case 2.755859375
▁of 0.07720947265625
▁Mr 0.05963134765625
. 0.0148162841796875
▁B 0.022705078125
: 0.56689453125
<0x0A> 0.04315185546875
To 7.171875
▁illustrate 1.734375
▁the 0.2208251953125
▁impact 0.72021484375
▁of 0.1038818359375
▁imm 1.140625
une 0.1072998046875
▁check 0.00970458984375
point 0.002681732177734375
▁in 0.0149383544921875
hib 7.462501525878906e-05
itors 0.0872802734375
▁in 1.724609375
▁mel 0.54833984375
an 6.61611557006836e-05
oma 0.0023097991943359375
▁treatment 1.0107421875
, 0.0633544921875
▁we 1.15234375
▁can 3.6640625
▁examine 2.708984375
▁Mr 2.728515625
. 0.005157470703125
▁B 0.0267791748046875
' 0.90185546875
s 0.0013570785522460938
▁case 0.1378173828125
. 0.12078857421875
▁Mr 0.51123046875
. 0.00743865966796875
▁B 0.004161834716796875
▁was 0.8173828125
▁diagn 0.87890625
osed 4.00543212890625e-05
▁with 0.02655029296875
▁met 2.078125
ast 0.0010852813720703125
atic 0.00988006591796875
▁mel 0.0928955078125
an 3.349781036376953e-05
oma 0.0005106925964355469
▁and 3.5546875
▁was 1.51171875
▁initially 2.2734375
▁respond 7.5625
ing 0.1251220703125
▁poor 3.5625
ly 3.898143768310547e-05
▁to 0.01580810546875
▁traditional 1.984375
▁treat 0.66015625
ments 3.2782554626464844e-05
. 0.3359375
▁However 1.345703125
, 0.0011606216430664062
▁upon 4.84375
▁starting 3.1796875
▁p 2.630859375
emb 0.00606536865234375
rol 0.00022232532501220703
iz 0.001323699951171875
um 0.002044677734375
ab 0.0001169443130493164
▁ther 2.294921875
apy 0.0022563934326171875
, 0.14013671875
▁his 0.61572265625
▁tum 2.86328125
or 0.1282958984375
▁re 4.8125
gress 0.0911865234375
ions 8.171875
▁were 0.7763671875
▁observed 2.001953125
, 1.6796875
▁leading 1.806640625
▁to 0.08740234375
▁a 0.87353515625
▁dur 2.578125
able 0.0017118453979492188
▁response 0.342041015625
▁with 2.732421875
▁no 2.44140625
▁disease 3.15234375
▁pro 1.08984375
gression 0.00020039081573486328
. 1.486328125
<0x0A> 1.5888671875
This 2.548828125
▁case 1.5126953125
▁exempl 2.47265625
ifies 0.005039215087890625
▁the 0.2467041015625
▁potential 1.9794921875
▁of 0.37353515625
▁imm 0.30615234375
une 0.053192138671875
▁check 0.01340484619140625
point 0.002468109130859375
▁in 0.012847900390625
hib 2.8371810913085938e-05
itors 0.04010009765625
▁in 0.411865234375
▁ach 3.85546875
ieving 2.9802322387695312e-05
▁long 1.1953125
- 0.007656097412109375
term 0.01227569580078125
▁rem 0.289306640625
ission 0.12335205078125
▁for 2.384765625
▁patients 0.41650390625
▁with 0.50537109375
▁advanced 0.92578125
▁mel 0.43994140625
an 3.8504600524902344e-05
oma 0.002696990966796875
. 0.25537109375
▁Mr 3.16796875
. 0.004669189453125
▁B 0.0015411376953125
' 0.337890625
s 0.00135040283203125
▁experience 2.857421875
▁highlight 2.109375
s 0.0008525848388671875
▁how 2.595703125
▁target 4.21484375
ed 0.0587158203125
▁ther 0.236572265625
ap 0.1348876953125
ies 5.364418029785156e-06
▁can 1.3037109375
▁effectively 3.970703125
▁halt 5.64453125
▁disease 2.517578125
▁pro 0.1767578125
gression 0.00029206275939941406
, 2.0625
▁extending 4.8828125
▁surv 1.140625
ival 0.0029201507568359375
▁and 1.458984375
▁impro 0.52734375
ving 2.288818359375e-05
▁the 3.533203125
▁quality 0.1396484375
▁of 0.00420379638671875
▁life 0.0239105224609375
▁for 0.1319580078125
▁patients 0.386962890625
▁facing 3.5859375
▁a 2.654296875
▁previously 6.71875
▁ble 10.21875
ak 0.0014772415161132812
▁pro 0.83447265625
gn 7.641315460205078e-05
osis 0.0006155967712402344
. 0.006988525390625
<0x0A> 0.420166015625
Con 3.537109375
clusion 0.43115234375
: 0.1920166015625
<0x0A> 5.30078125
The 1.7294921875
▁adv 1.9306640625
anc 0.273681640625
ements 1.6450881958007812e-05
▁in 0.08148193359375
▁mel 0.341552734375
an 0.00011038780212402344
oma 0.0003218650817871094
▁treatment 0.06524658203125
▁through 5.10546875
▁imm 1.294921875
une 0.130859375
▁check 0.0106658935546875
point 0.00489044189453125
▁in 0.0080718994140625
hib 4.1484832763671875e-05
itors 0.017822265625
▁and 0.6240234375
▁adj 0.019439697265625
uv 0.0017480850219726562
ant 0.0013828277587890625
▁ther 0.021209716796875
ap 0.06329345703125
ies 1.33514404296875e-05
▁have 0.291259765625
▁significantly 3.427734375
▁transformed 4.1015625
▁the 0.333251953125
▁pro 2.673828125
gn 0.0012531280517578125
osis 0.0159759521484375
▁and 1.9375
▁quality 1.25390625
▁of 0.01416778564453125
▁life 0.006237030029296875
▁for 0.1551513671875
▁patients 0.156494140625
▁at 1.0380859375
▁different 0.25830078125
▁stages 0.00850677490234375
. 1.822265625
▁Through 4.29296875
▁extensive 6.1484375
▁research 0.278076171875
▁and 0.37841796875
▁evidence 5.578125
, 1.6923828125
▁it 2.388671875
▁is 0.494140625
▁evident 1.3583984375
▁that 0.01042938232421875
▁these 0.7001953125
▁treat 1.056640625
ments 6.628036499023438e-05
▁offer 2.455078125
▁the 3.64453125
▁potential 1.212890625
▁for 1.9462890625
▁long 1.2978515625
- 0.00856781005859375
term 0.0151519775390625
▁rem 0.38134765625
ission 0.0814208984375
, 1.87109375
▁particularly 5.8671875
▁when 3.458984375
▁combined 1.2939453125
▁with 0.1649169921875
▁personal 8.703125
ized 0.0149383544921875
▁adj 6.421875
uv 0.01554107666015625
ant 0.0026493072509765625
▁ther 0.1966552734375
ap 0.358154296875
ies 7.867813110351562e-06
. 0.31640625
▁As 3.580078125
▁demonstrated 6.703125
▁by 0.8740234375
▁Mr 0.60009765625
. 0.00565338134765625
▁B 0.00540924072265625
' 0.270751953125
s 0.00463104248046875
▁case 0.1600341796875
, 0.056488037109375
▁these 0.98095703125
▁adv 2.146484375
anc 0.110107421875
ements 2.0384788513183594e-05
▁bring 7.015625
▁hope 0.60302734375
▁for 1.537109375
▁patients 1.0478515625
▁facing 2.150390625
▁advanced 1.81640625
▁mel 0.15576171875
an 6.198883056640625e-05
oma 0.00690460205078125
, 1.5537109375
▁prom 6.16796875
ising 0.07861328125
▁increased 5.59765625
▁surv 0.2900390625
ival 0.008819580078125
▁rates 0.414794921875
▁and 0.281005859375
▁improved 1.34765625
▁overall 3.697265625
▁out 4.57421875
comes 0.140625
. 0.10809326171875
▁Cont 8.84375
in 0.216064453125
ued 0.018035888671875
▁research 0.52685546875
▁and 0.5732421875
▁innov 2.109375
ation 0.173095703125
▁in 1.6533203125
▁this 1.2626953125
▁field 0.59375
▁hold 4.78515625
▁promise 1.8740234375
▁for 0.2081298828125
▁further 2.21484375
▁adv 1.009765625
anc 0.1629638671875
ements 1.4066696166992188e-05
, 2.599609375
▁offering 2.07421875
▁hope 2.314453125
▁to 1.4443359375
▁count 4.21484375
less 1.2159347534179688e-05
▁individuals 1.298828125
▁batt 2.67578125
ling 0.0002765655517578125
▁this 0.591796875
▁ag 2.869140625
gress 0.0003826618194580078
ive 0.0007658004760742188
▁form 1.4990234375
▁of 0.0011186599731445312
▁skin 0.55224609375
▁cancer 0.00399017333984375
. 0.029327392578125
